Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOS006215 in advanced solid tumors
NCT06877533Phase 1Terminated
- Sponsor
- iTeos Therapeutics
- Start
- Apr 2025
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of EOS-215 in solid tumor (advanced stage) (2 arms), sponsored by iTeos Therapeutics. Primary endpoints: Incidence of Dose-Limiting Toxicities, Incidence of Adverse Events and Serious Adverse Events up to 24 months and 2 more. Started Apr 2025; status: terminated.
02
Drugs
EOS-215
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06877533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06877533.